Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeuroSTAT in Severe Traumatic Brain Injury
NCT01825044Phase 2Completed
- Sponsor
- Abliva AB
- Start
- Apr 2013
- Primary completion
- Sep 2017
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of NeuroSTAT in traumatic brain injury (TBI) (2 arms), sponsored by Abliva AB. Primary endpoints: Pharmacokinetics of Ciclosporin in whole blood at 8 days and Incidence of adverse events at 38 days. Started Apr 2013; status: completed.
02
Drugs
NeuroSTAT
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT01825044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01825044.